- Home
- ZSQR vs PLX Comparison
ZSQR vs PLX Comparison
Compare ZSQR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZSQR | PLX |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 182.9M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ZSQR | PLX |
|---|---|---|
| Price | $3.09 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 307.1K | ★ 796.1K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.27 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $1,363,045.00 | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.81 | $1.60 |
| 52 Week High | $16.62 | $3.19 |
Technical Indicators
Market Signals| Indicator | ZSQR | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 67.52 |
| Support Level | $2.81 | $2.59 |
| Resistance Level | $4.38 | $3.03 |
| Average True Range (ATR) | 0.46 | 0.09 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 20.16 | 96.20 |
Price Performance
Historical ComparisonAbout ZSQR Z Squared Inc. Common Stock
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.